Real-world study compares the efficacy and safety of axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel), ...

Yi Lin, MD, PhD, hematologist and oncologist, Mayo Clinic, discusses the efficacy of ciltacabtagene autoleucel (cilta-cel) chimeric antigen receptor T-cell therapy vs standard treatments for patients ...

For patients with microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal cancer ...

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free ...

AstraZeneca and Merck report Lynparza's significant survival benefits in high-risk breast cancer and Keytruda combo results ...

Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced ...

For patients with microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal can ...

Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE) to current standard-of-care first ...

Pfizer (PFE) and Alliance Foundation Trials announced results from the Phase 3 PATINA trial demonstrating that the addition of Ibrance to ...

Pfizer, facing increasing pressure from Novartis, is touting a Phase III win for Ibrance as the first clinical evidence supporting the CDK4/6 inhibitor class’ use in patients with a specific type of ...

Cardiff Oncology's phase 2 trial of onvansertib in mCRC shows promising results, with improved response rates and potential ...